Merck & Co Inc. (MRK) announced on Monday that China's National Medical Products Administration (NMPA) has granted approval for the use of Keytruda in combination with chemotherapy as a neoadjuvant treatment, followed by its use as an adjuvant therapy post-surgery for patients diagnosed with non-small cell lung cancer (NSCLC).
This approval is underpinned by the findings from the KEYNOTE-671 study, in which Keytruda was assessed alongside chemotherapy as a pre-surgical treatment and as a standalone therapy post-surgery for patients with stage II, IIIA, or IIIB NSCLC. The study's data demonstrated a 28% reduction in the risk of death with this treatment protocol.
This marks the fourth approved indication for Keytruda in the treatment of NSCLC in China.
The material has been provided by InstaForex Company - www.instaforex.com
This approval is underpinned by the findings from the KEYNOTE-671 study, in which Keytruda was assessed alongside chemotherapy as a pre-surgical treatment and as a standalone therapy post-surgery for patients with stage II, IIIA, or IIIB NSCLC. The study's data demonstrated a 28% reduction in the risk of death with this treatment protocol.
This marks the fourth approved indication for Keytruda in the treatment of NSCLC in China.
The material has been provided by InstaForex Company - www.instaforex.com